ORGONasdaq

Organogenesis Holdings Inc.

Healthcare·Healthcare·Commercial·Canton, MA, United States

Organogenesis Holdings Inc. (ORGO): 20 pipeline candidates · ~4 mo cash runway. Updated within the last hour.

7.6/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway1.1

4.1 months

Financial Health9.1

D/E 0.57 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

20 candidates

Catalyst MomentumN/A

N/A

Insider Signal8.0

2 buys · 0 sells (180d)

A transparent, data-derived signal for Organogenesis Holdings Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$301.1M

Cash

$92.1M

Quarterly Burn

$106.1M

Runway

4.1 mo

Revenue

$37.2M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Oct 2026
Today~7 mo out
Catalyst within runway

Pipeline (20 candidates)

Showing 10 of 20 candidates. Sign up for full pipeline.

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

119

Total value held

$111.6M

HolderSharesValue
morgan stanley11,616,795$27.5M
vanguard capital management llc5,801,632$13.7M
blackrock, inc.4,899,751$11.6M
dimensional fund advisors lp2,891,006$6.9M
d. e. shaw & co., inc.2,297,974$5.4M
geode capital management, llc1,783,964$4.2M
deutsche bank ag\1,705,681$4.0M
state street corp1,525,108$3.6M
vanguard portfolio management llc1,449,092$3.4M
renaissance technologies llc1,068,538$2.5M

Showing top 10 of 119 institutional holders of Organogenesis Holdings Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Gary S. Gillheeney Sr.

Frequently asked questions

How many drug candidates are in Organogenesis Holdings Inc.'s pipeline?

Organogenesis Holdings Inc. (ORGO) has 20 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Organogenesis Holdings Inc.'s lead drug candidate?

Organogenesis Holdings Inc.'s most advanced tracked candidate is apligraf (Approved) for General, Plastic Surgery.

What is Organogenesis Holdings Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Organogenesis Holdings Inc. has approximately 4.1 months of cash runway.

What is Organogenesis Holdings Inc.'s market capitalization?

Organogenesis Holdings Inc.'s market capitalization is approximately $301.1M.

Who is the CEO of Organogenesis Holdings Inc.?

Mr. Gary S. Gillheeney Sr. is the chief executive officer of Organogenesis Holdings Inc. (ORGO).

Get the full picture on Organogenesis Holdings Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.